Drug Profile

ALM 27134

Alternative Names: ALM-27134; Anti-human IL1RAP antagonist mAb; Anti-IL-1RAP mAb - Almirall S.A; ISB-880

Latest Information Update: 06 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ichnos Sciences
Developer Almirall S.A.
Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
Mechanism of Action Interleukin-1 receptor accessory protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

24 Feb 2025 Almirall S.A. plans a phase II trial for Hidradenitis suppurativa later this year
22 Jul 2024 Almirall plans a phase II trial for Autoimmune disorders (Parenteral) in the second half of 2024
30 Jan 2024 Glenmark and Ichnos enters into an alliance to form 'Ichnos Glenmark Innovation'

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com